Journal Article
. 2019 Jul; 14(7):e0218434.
doi: 10.1371/journal.pone.0218434.

Does chemotherapy improve survival in patients with nodal positive luminal A breast cancer? A retrospective Multicenter Study

Daniel Herr 1 Manfred Wischnewsky 2 Ralf Joukhadar 1 Olivia Chow 1 Wolfgang Janni 3 Elena Leinert 3 Visnja Fink 3 Tanja Stüber 1 Carolin Curtaz 1 Rolf Kreienberg 3 Maria Blettner 4 Daniel Wollschläger 4 Achim Wöckel 1 
Affiliations
  • PMID: 31283775
  •     32 References
  •     8 citations

Abstract

Background: In this study based on the BRENDA data, we investigated the impact of endocrine ± chemotherapy for luminal A, nodal positive breast cancer on recurrence free (RFS) and overall survival (OS). In addition, we analysed if tumor size of luminal A breast cancer influences survival in patients with the same number of positive lymph nodes.

Methods: In this retrospective multi-centre cohort study data of 1376 nodal-positive patients with primary diagnosis of luminal A breast cancer during 2001-2008 were analysed. The results were stratified by therapy and adjusted by age, tumor size and number of affected lymph nodes.

Results: In our study population, patients had a good to excellent prognosis (5-year RFS: 91% and tumorspecific 5-year OS 96.5%). There was no significant difference in RFS stratified by patients with only endocrine therapy and with endocrine plus chemo-therapy. Patients with 1-3 affected lymph nodes had no significant differences in OS treated only with endocrine therapy or with endocrine plus chemotherapy, independent of tumor size. Patients with large tumors and more than 3 affected lymph nodes had a significant worse survival as compared to the small tumors. However, despite the worse prognosis of those, adjuvant chemotherapy failed in order to improve RFS.

Conclusions: According to our data, nodal positive patients with luminal A breast cancer have, if any, a limited benefit of adjuvant chemotherapy. Tumor size and nodal status seem to be of prognostic value in terms of survival, however both tumor size as well as nodal status were not predictive for a benefit of adjuvant chemotherapy.

Breast Cancer Survival Defined by the ER/PR/HER2 Subtypes and a Surrogate Classification according to Tumor Grade and Immunohistochemical Biomarkers.
Carol A Parise, Vincent Caggiano.
J Cancer Epidemiol, 2014 Jun 24; 2014. PMID: 24955090    Free PMC article.
Highly Cited.
Is adjuvant chemotherapy omissible in women with T1-2 stage, node-positive, luminal A type breast cancer?
Hee Yong Kwak, Byung Joo Chae, +5 authors, Byung Joo Song.
J Chemother, 2015 May 15; 27(5). PMID: 25974160
If Chemotherapy Is Indicated, Give the Optimal Regimen!
Volker Möbus.
Breast Care (Basel), 2016 Apr 07; 11(1). PMID: 27051388    Free PMC article.
Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199.
Sylvia Adams, Robert J Gray, +13 authors, Sunil S Badve.
J Clin Oncol, 2014 Jul 30; 32(27). PMID: 25071121    Free PMC article.
Highly Cited.
Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial.
Judith Hugh, John Hanson, +11 authors, Charles Vogel.
J Clin Oncol, 2009 Feb 11; 27(8). PMID: 19204205    Free PMC article.
Highly Cited.
Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial.
Sandra M Swain, Gong Tang, +17 authors, Norman Wolmark.
J Clin Oncol, 2013 Aug 14; 31(26). PMID: 23940225    Free PMC article.
Breast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response.
E H Lips, L Mulder, +5 authors, J Wesseling.
Breast Cancer Res Treat, 2013 Jul 06; 140(1). PMID: 23828499    Free PMC article.
Adjuvant chemotherapy in luminal breast cancers.
Elgene Lim, Eric P Winer.
Breast, 2011 Nov 02; 20 Suppl 3. PMID: 22015279
Review.
Reproductive history and risk of three breast cancer subtypes defined by three biomarkers.
Amanda I Phipps, Diana S M Buist, +4 authors, Christopher I Li.
Cancer Causes Control, 2010 Dec 25; 22(3). PMID: 21184265    Free PMC article.
Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011.
A Goldhirsch, W C Wood, +4 authors, Panel members.
Ann Oncol, 2011 Jun 29; 22(8). PMID: 21709140    Free PMC article.
Highly Cited.
Randomised phase III trial of FEC120 vs EC-docetaxel in patients with high-risk node-positive primary breast cancer: final survival analysis of the ADEBAR study.
W Janni, N Harbeck, +9 authors, M Kiechle.
Br J Cancer, 2016 Apr 01; 114(8). PMID: 27031854    Free PMC article.
Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial.
V Möbus, C Jackisch, +14 authors, AGO Breast Study Group (AGO-B).
Ann Oncol, 2017 Oct 27; 29(1). PMID: 29069370
Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer.
Donald A Berry, Constance Cirrincione, +9 authors, Eric P Winer.
JAMA, 2006 Apr 13; 295(14). PMID: 16609087    Free PMC article.
Highly Cited.
Identifying the impact of inflammatory breast cancer on survival: a retrospective multi-center cohort study.
J Diessner, R Van Ewijk, +7 authors, L Schwentner.
Arch Gynecol Obstet, 2015 Mar 31; 292(3). PMID: 25814296
Is adjuvant chemotherapy necessary for Luminal A-like breast cancer?
Halil Taskaynatan, Yuksel Kucukzeybek, +7 authors, Mustafa Oktay Tarhan.
J BUON, 2018 Oct 26; 23(4). PMID: 30358189
Omission of chemotherapy for low-grade, luminal A N1 breast cancer: Patterns of care and clinical outcomes.
Waqar Haque, Vivek Verma, +3 authors, Bin S Teh.
Breast, 2018 Jul 15; 41. PMID: 30007270
Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) - Part 2 with Recommendations for the Therapy of Primary, Recurrent and Advanced Breast Cancer.
Achim Wöckel, Jasmin Festl, +94 authors, Stephanie Stangl.
Geburtshilfe Frauenheilkd, 2018 Dec 26; 78(11). PMID: 30581198    Free PMC article.
Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study.
Volker Moebus, Christian Jackisch, +14 authors, Michael Untch.
J Clin Oncol, 2010 May 12; 28(17). PMID: 20458045
Dose-dense chemotherapy in nonmetastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials.
Luisa Bonilla, Irit Ben-Aharon, +3 authors, Salomon M Stemmer.
J Natl Cancer Inst, 2010 Nov 26; 102(24). PMID: 21098761    Free PMC article.
Systematic Review.
Repeated observation of breast tumor subtypes in independent gene expression data sets.
Therese Sorlie, Robert Tibshirani, +13 authors, David Botstein.
Proc Natl Acad Sci U S A, 2003 Jun 28; 100(14). PMID: 12829800    Free PMC article.
Highly Cited.
Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.
Marc L Citron, Donald A Berry, +18 authors, Larry Norton.
J Clin Oncol, 2003 Apr 02; 21(8). PMID: 12668651
Highly Cited.
Cyclophosphamide, methotrexate, and fluorouracil; oral cyclophosphamide; levamisole; or no adjuvant therapy for patients with high-risk, premenopausal breast cancer.
Bent Ejlertsen, Henning T Mouridsen, +5 authors, Danish Breast Cancer Cooperative Group.
Cancer, 2010 Feb 27; 116(9). PMID: 20186830
Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.
Gunter von Minckwitz, Michael Untch, +14 authors, Sibylle Loibl.
J Clin Oncol, 2012 Apr 18; 30(15). PMID: 22508812
Highly Cited.
Do Patients with Luminal A Breast Cancer Profit from Adjuvant Systemic Therapy? A Retrospective Multicenter Study.
Joachim Diessner, Manfred Wischnewsky, +8 authors, Achim Wöckel.
PLoS One, 2016 Dec 20; 11(12). PMID: 27992550    Free PMC article.
Molecular portraits of human breast tumours.
C M Perou, T Sørlie, +15 authors, D Botstein.
Nature, 2000 Aug 30; 406(6797). PMID: 10963602
Highly Cited.
Breast cancer tumor size, nodal status, and prognosis: biology trumps anatomy.
Elizabeth A Comen, Larry Norton, Joan Massagué.
J Clin Oncol, 2011 May 25; 29(19). PMID: 21606411
A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer.
Torsten O Nielsen, Joel S Parker, +12 authors, Matthew J Ellis.
Clin Cancer Res, 2010 Sep 15; 16(21). PMID: 20837693    Free PMC article.
Highly Cited.
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.
T Sørlie, C M Perou, +14 authors, A L Børresen-Dale.
Proc Natl Acad Sci U S A, 2001 Sep 13; 98(19). PMID: 11553815    Free PMC article.
Highly Cited.
Prognostic Significance of Adjuvant Chemotherapy Induced Amenorrhea in Luminal A and B Subtypes.
Çetin Ordu, Kezban Nur Pilancı, +14 authors, Vahit Özmen.
Eur J Breast Health, 2018 Aug 21; 14(3). PMID: 30123884    Free PMC article.
Deconstructing the molecular portraits of breast cancer.
Aleix Prat, Charles M Perou.
Mol Oncol, 2010 Dec 15; 5(1). PMID: 21147047    Free PMC article.
Highly Cited. Review.
Evaluation of clinical parameters influencing the development of bone metastasis in breast cancer.
Joachim Diessner, Manfred Wischnewsky, +9 authors, Catharina Bartmann.
BMC Cancer, 2016 May 14; 16. PMID: 27175930    Free PMC article.
Histologic grade remains a prognostic factor for breast cancer regardless of the number of positive lymph nodes and tumor size: a study of 161 708 cases of breast cancer from the SEER Program.
Arnold M Schwartz, Donald Earl Henson, Dechang Chen, Sivasankari Rajamarthandan.
Arch Pathol Lab Med, 2014 Jul 31; 138(8). PMID: 25076293
Impact of deviation from guideline recommended treatment on breast cancer survival in Asia.
Peh Joo Ho, Samuel Guan Wei Ow, +12 authors, Mikael Hartman.
Sci Rep, 2020 Jan 30; 10(1). PMID: 31992769    Free PMC article.
Risk factors of distant metastasis after surgery among different breast cancer subtypes: a hospital-based study in Indonesia.
Sumadi Lukman Anwar, Widya Surya Avanti, +5 authors, Wahyu Wulaningsih.
World J Surg Oncol, 2020 Jun 01; 18(1). PMID: 32473643    Free PMC article.
Nodal positivity decreases with age in women with early-stage, hormone receptor-positive breast cancer.
Stephanie M Downs-Canner, Charles E Gaber, +4 authors, David W Ollila.
Cancer, 2019 Dec 21; 126(6). PMID: 31860136    Free PMC article.
Landmark trials in the medical oncology management of early stage breast cancer.
Whitney Hensing, Cesar A Santa-Maria, Lindsay L Peterson, Jennifer Y Sheng.
Semin Oncol, 2020 Sep 17; 47(5). PMID: 32933761    Free PMC article.
Review.
Efficacy of chemotherapy for lymph node-positive luminal A subtype breast cancer patients: an updated meta-analysis.
Yilun Li, Li Ma.
World J Surg Oncol, 2020 Dec 04; 18(1). PMID: 33267822    Free PMC article.
Review.
Establishment and Validation of Novel Clinical Prognosis Nomograms for Luminal A Breast Cancer Patients with Bone Metastasis.
QiHao Tu, Chuan Hu, +9 authors, XueXiao Ma.
Biomed Res Int, 2021 Jan 26; 2020. PMID: 33490234    Free PMC article.
Establishing a prediction model of axillary nodal burden based on the combination of CT and ultrasound findings and the clinicopathological features in patients with early-stage breast cancer.
Xianfu Sun, Qiang Zhang, +3 authors, Shengze Zhang.
Gland Surg, 2021 Mar 13; 10(2). PMID: 33708557    Free PMC article.
Breast Cancer Therapeutics and Biomarkers: Past, Present, and Future Approaches.
Jason Schick, Raquel P Ritchie, Carolina Restini.
Breast Cancer (Auckl), 2021 May 18; 15. PMID: 33994789    Free PMC article.
Review.